Results 121 to 130 of about 2,925,110 (170)

A Fusion Deep Learning Model for Predicting Adverse Drug Reactions Based on Multiple Drug Characteristics. [PDF]

Life (Basel)
Ou Q, Jiang X, Guo Z, Jiang J, Gan Z, Han F, Cai Y.   +6 more
europepmc   +1 more source

Incidence of Adverse Drug Reactions Among HIV Patients on Antiretroviral Drugs in Ethiopia: A Systematic Review and Meta-Analysis. [PDF]

AIDS Res Treat
Endalamew SG, Assefa SK, Getachew MS, Arage FG, Asgedom DK, Terefe B, Teshome DF.   +6 more
europepmc   +1 more source

Assessing the Real-World Safety of Regadenoson for Myocardial Perfusion Imaging: Insights from a Comprehensive Analysis of FAERS Data. [PDF]

J Clin Med
Xu X, Guo Q, Li Y, Zhai C, Mao Y, Zhang Y, Zhang L, Zhang Y.   +7 more
europepmc   +1 more source

Signal detection and safety analysis of three tyrosine kinase inhibitors for HER-2 positive breast cancer: a retrospective study based on the FAERS database. [PDF]

Front Pharmacol
Tang X, Wang C, Li Y, Tang J, Zhang G, Chen L.   +5 more
europepmc   +1 more source

Gastrointestinal toxicity of antibody-drug conjugates: a pharmacovigilance study using the FAERS database. [PDF]

BMC Pharmacol Toxicol
Shi Y, Yao K, Zhao J, Yue Y, Wu H.
europepmc   +1 more source

The characteristics of adverse reactions of three anti-prostate cancer drugs based on Vigiaccess database and bibliometric analysis. [PDF]

Front Pharmacol
Wang J, You J, Huang W, Yuan C, Chen J, Wang F, Wang W, Zhang L.   +7 more
europepmc   +1 more source

Employing bibliometrics and natural language processing (NLP) to analyse real-world applications of adverse drug reaction. [PDF]

Explor Res Clin Soc Pharm
Dsouza VS, Leyens L, Brand A.
europepmc   +1 more source

Analysis of Reporting Trends of Serious Adverse Events Associated With Anti-Obesity Drugs. [PDF]

Pharmacol Res Perspect
Raičević BB, Belančić A, Mirković N, Janković SM.   +3 more
europepmc   +1 more source

Oculogyric Crisis in Early Pregnancy: Lessons Learned From a Rare Adverse Effect of Metoclopramide. [PDF]

Cureus
Sivagurunathan K, Kaneshamoorthy P, Jegathesan N, Thampipillai P.   +3 more
europepmc   +1 more source

Off-label use of anlotinib in malignancies' treatment: efficacy and management of adverse reactions. [PDF]

Pharmacol Rep
Wang G, Wang Y, Jin C, Sun X.
europepmc   +1 more source